Daewoong expands botulinum toxin Nabota into 10 Middle Eastern countries

Korea's Daewoong Pharmaceutical has extended its botulinum toxin Nabota to 10 of the 20 countries in the Middle East and North Africa after signing export contracts with Iraq and Bahrain, the company said Monday.

The expansion follows launches this year in Saudi Arabia and Qatar and builds on earlier entries since 2020 in the UAE, Turkey and Egypt. Daewoong said it is treating the Middle East as a strategic hub after establishing Nabota in North America, Europe and Latin America.

The company aims to pitch Nabota as a premium toxin through physician training and academic support to boost procedure quality. Daewoong plans to host its first region-specific Nabota Master Class, NMC MENA, in Saudi Arabia later this year, with about 100 physicians expected.

Demand signals remain strong: more than half of the region’s population is under 30, and aesthetics trends are spreading via social media, according to Daewoong.